Cargando…

Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)

BACKGROUND: The efficacy and safety of nivolumab versus chemotherapy was evaluated in the Japanese subpopulation from the overall intent-to-treat (ITT) population of the ATTRACTION-3 trial conducted in patients with advanced esophageal squamous cell carcinoma (ESCC) as second-line treatment. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Masanobu, Kato, Ken, Okada, Morihito, Chin, Keisho, Kadowaki, Shigenori, Hamamoto, Yasuo, Doki, Yuichiro, Kubota, Yutaro, Kawakami, Hisato, Ogata, Takashi, Hara, Hiroki, Muto, Manabu, Nakashima, Yuichiro, Ishihara, Ryu, Tsuda, Masahiro, Motoyama, Satoru, Kodani, Mamoru, Kitagawa, Yuko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794205/ https://www.ncbi.nlm.nih.gov/pubmed/33170461 http://dx.doi.org/10.1007/s10388-020-00794-x

Ejemplares similares

Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
por: Okada, Morihito, et al.
Publicado: (2022)

Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3
por: Chin, Keisho, et al.
Publicado: (2022)

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)
por: Kato, Ken, et al.
Publicado: (2022)

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
por: Boku, Narikazu, et al.
Publicado: (2021)

Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)
por: Satoh, Taroh, et al.
Publicado: (2021)

The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy
por: Inagaki, Chiaki, et al.
Publicado: (2023)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
por: Fujimoto, Nobukazu, et al.
Publicado: (2020)

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
por: Chen, Li-Tzong, et al.
Publicado: (2019)

Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer
por: Kato, Ken, et al.
Publicado: (2020)

An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
por: Kawakami, Hisato, et al.
Publicado: (2021)

Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review
por: Mori, Ryota, et al.
Publicado: (2022)

Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2018)

Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
por: Kang, Yoon-Koo, et al.
Publicado: (2021)

Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer
por: Hagi, Takaomi, et al.
Publicado: (2020)

A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)
por: Kato, Ken, et al.
Publicado: (2018)

Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
por: Satoh, Taroh, et al.
Publicado: (2019)

Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2020)

Nivolumab-induced interstitial lung disease in a patient with gastric cancer
por: Kimura, Akie, et al.
Publicado: (2019)

Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer
por: Yasuda, Yuichiro, et al.
Publicado: (2017)

Long-term outcome of adrenalectomy for metastasis resulting from colorectal cancer with other metastatic sites: A report of 3 cases
por: Uemura, Mamoru, et al.
Publicado: (2016)

Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy
por: Mitani, Seiichiro, et al.
Publicado: (2016)

Appropriateness of the institute certification system for esophageal surgeries by the Japan Esophageal Society: evaluation of survival outcomes using data from the National Database of Hospital-Based Cancer Registries in Japan
por: Motoyama, Satoru, et al.
Publicado: (2018)

Esophagectomy performed at institutes certified by the Japan Esophageal Society provide long-term survival advantages to esophageal cancer patients: second report analyzing 4897 cases with propensity score matching
por: Motoyama, Satoru, et al.
Publicado: (2020)

Epithelial Cell Transformation and Senescence as Indicators of Genome Aging: Current Advances and Unanswered Questions
por: Kitakaze, Masatoshi, et al.
Publicado: (2021)

Safety evaluation of fixed‐dose nivolumab in patients with gastric cancer
por: Iikura, Yusuke, et al.
Publicado: (2022)

Rapidly growing proliferative pulmonary chondroma: A case report
por: Uchida, Tsuyoshi, et al.
Publicado: (2022)

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
por: Kimbara, Shiro, et al.
Publicado: (2018)

Reduction in thrombogenic activity and thrombocytopenia after transcatheter aortic valve implantation — The ATTRACTIVE-TTAS study
por: Ishii, Masanobu, et al.
Publicado: (2019)

Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer
por: Bando, Hideaki, et al.
Publicado: (2022)

Predictive biomarkers for the efficacy of nivolumab as ≥ 3(rd)-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial
por: Kim, Jwa Hoon, et al.
Publicado: (2022)

Chemoenzymatic synthesis of 3-ethyl-2,5-dimethylpyrazine by L-threonine 3-dehydrogenase and 2-amino-3-ketobutyrate CoA ligase/L-threonine aldolase
por: Motoyama, Tomoharu, et al.
Publicado: (2021)

Behavioral Assessment of a Humanoid Robot When Attracting Pedestrians in a Mall
por: Okafuji, Yuki, et al.
Publicado: (2022)

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
por: Yoshikawa, Takaki, et al.
Publicado: (2019)

Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer
por: Jun, Chen, et al.
Publicado: (2023)

Perspective beyond Cancer Genomics: Bioenergetics of Cancer Stem Cells
por: Ishii, Hideshi, et al.
Publicado: (2010)

Essential updates 2021/2022: Perioperative and surgical treatments for gastric and esophagogastric junction cancer
por: Yanagimoto, Yoshitomo, et al.
Publicado: (2023)

Long‐term survival of a patient with lung cancer treated with pembrolizumab after recurrent cardiac tamponade
por: Uchida, Tsuyoshi, et al.
Publicado: (2022)

Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2021)

Pure laparoscopic liver resection for giant liver hemangioma with extrahepatic growth based on preoperative 3-dimensional simulation: A case report
por: Okumura, Yuichiro, et al.
Publicado: (2019)

Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization
por: Yoshioka, Yuichiro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bgjsjq3jhp8otps62o7ff0i206